Deal overview
| Target | MERUS NV |
|---|---|
| Bidder | GENMAB A/S |
| Price | £80.00 Full version or £25.00 Light version |
| Publication Date | Sep 29, 2025 |
| Abstract | On 29 September 2025, it was announced that Genmab Holding II BV ("Genmab Holding"), a subsidiary of the quoted Danish biotechnology company Genmab A/S ("Genmab"), had entered into an agreement to acquire Genmab's Nasdaq-quoted Dutch peer Merus NV ("Merus") for a cash consideration of US$97.00 per share. The terms implied a total equity value for Merus of approximately ... |
| Number of pages (Full version) | 8 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
